Generalized Anxiety Disorder Market Size & Growth Analysis

Generalized anxiety disorder is characterized by intense fear and worry over daily activities for no apparent reason. The patient cannot stop worrying about health , family, finances, or work, and eventually anxiety dominates the thought that interferes with the day-to-day functioning of the individual. Symptoms of generalized anxiety disorder include an unrealistic view of problems, muscle tension, headache, sweating, and tiredness. The disorder is progressive and can occur throughout the life cycle, although the risk is maximum between childhood and middle age. Global anxiety disorders and depression treatment market size was estimated at U$ xx.x billion in 2022 and is projected to show steady growth of CAGR xx% during the forecast period 2023 - 2030. GAD is diagnosed when a person has been overly concerned with daily problems for more than six months and has three or more symptoms. According to the Centers for Disease Control and Prevention (CDC), the incidence of disorder is higher in women than in men. Psychotherapy is generally preferable to a GAD patient rather than a medication that teaches a person different ways to react and thinking in various life situations. Growing demand for antidepressants is leading to growth given the limited side effects associated with these medications and increasing awareness among consumers. In addition, the existence of favorable reimbursement policies for medicinal products in developing countries and therapies coupled with their high success levels are anticipated to push growth over the forecast period 2023 - 2030.

GENERALIZED ANXIETY DISORDER MARKET REPORT COVERAGE

Click Here To Download Sample

Market Segmentation

Generalized Anxiety Disorder Market - By Therapeutics Type

• Antidepressant
• Benzodiazepiness
• Others

Antidepressants are first-line treatment for people with GAD and thus have the highest global market share. Antidepressants are used to treat major depressive disorder (MDD) as well as mental illnesses including panic disorder, phobia, obsessive-compulsive disorder and traumatic stress disorders. Increasing prevalence of these diseases is projected to increase potential demand for successful medicinal products. The increasing geriatric population vulnerable to depression and the increasing prevalence of anxiety disorders are further contributing to the increasing demand for antidepressants over the forecast period to treat mental illnesses. In addition, the introduction of technologically advanced therapies, such as medical implants used to stimulate the brain and virtual reality stimulation therapies using smartphone-based software, provides patients with creative alternative treatments.

Geographical Analysis

This global report on generalized anxiety disorder market is analyzed based on the following regions:

• North America
• Europe
• Asia Pacific
• RoW

North America dominated the industry in 2022, largely owing to the increase incidence of depressive and anxiety disorders in the region. Additionally, supporting government policies, the availability of various branded formulations, and higher levels of awareness are anticipated to boost vertical growth. Asia Pacific is projected to have lucrative growth owing to increasing disposable incomes of individuals and high demand for antidepressants given the high prevalence of anxiety disorders. In addition, improving healthcare infrastructure in emerging countries and increasing awareness of improved treatment options are factors that further contribute to this growth.

Key Market Players

Some of the key players operating  with Generalized anxiety disorders  market space are GlaxoSmithKline plc, Pfizer, Inc., Eli Lilly and Company, H. Lundbeck A / S, Forest Laboratories, Inc., AstraZeneca, Merck & Company , Inc., Johnson & Johnson, and Sanofi-Aventis.